Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

BCX-1777 in Treating Patients With Refractory Cutaneous T-Cell Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00061880
Recruitment Status : Completed
First Posted : June 6, 2003
Last Update Posted : May 30, 2013
Sponsor:
Information provided by:
National Cancer Institute (NCI)

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

RATIONALE: BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth.

PURPOSE: Phase I/II trial to study the effectiveness BCX-1777 in treating patients who have refractory cutaneous T-cell lymphoma.


Condition or disease Intervention/treatment Phase
Lymphoma Drug: forodesine hydrochloride Phase 1 Phase 2

Detailed Description:

OBJECTIVES:

  • Determine the maximum tolerated dose of BCX-1777 in patients with refractory cutaneous T-cell lymphoma.
  • Determine the efficacy of this drug in these patients.
  • Determine the toxicity profile of this drug in these patients.
  • Correlate plasma concentration of deoxyguanosine with clinical response and toxicity in patients treated with this drug.
  • Determine the provisional optimal biological dose of this drug in these patients.

OUTLINE: This is an open-label, nonrandomized, dose-escalation, multicenter study.

  • Phase I: Patients receive BCX-1777 IV over 30 minutes every 12 hours on days 1-5 (a total of 9 doses). Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of BCX-1777 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which no more than 2 of 6 patients experience dose-limiting toxicity.

  • Phase II: Patients receive treatment as in phase I at the MTD of BCX-1777. Patients (including those who respond to treatment) are followed at 14 and 30 days, monthly for 6 months, every 2 months for 6 months, and then every 6 months thereafter.

PROJECTED ACCRUAL: A total of 3-64 patients (3-24 for phase I and 40 for phase II) will be accrued for this study.


Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1-2 Multi-Center Study of Intravenous BCX-1777 in Patients With Refractory Cutaneous T-Cell Lymphoma (CTCL)
Study Start Date : February 2003
Actual Primary Completion Date : January 2005
Actual Study Completion Date : January 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Histologically confirmed cutaneous T-cell lymphoma (CTCL)

    • Any stage except IA patch only

  • Previously treated according to 1 of the following:

    • Stage IA plaque, IB, or IIA:

      • At least 4 prior conventional and/or experimental regimens (topical or systemic, including psoralen-ultraviolet light [PUVA] and systemic corticosteroids)

    • Stage IIB, III, or IV:

      • At least 1 prior systemic regimen (systemic corticosteroids and PUVA do not count as systemic regimens for this purpose) NOTE: Repeated use of the same regimen is considered one regimen
  • Measurable disease

PATIENT CHARACTERISTICS:

Age

  • 18 and over

Performance status

  • ECOG 0-3

Life expectancy

  • At least 3 months

Hematopoietic

  • Granulocyte count at least 2,000/mm^3
  • Platelet count at least 75,000/mm^3
  • Hemoglobin at least 10.0 g/dL

Hepatic

  • Bilirubin no greater than 1.5 times upper limit of normal (ULN) (unless due to Gilbert's syndrome)
  • ALT no greater than 2 times ULN
  • Alkaline phosphatase no greater than 2 times ULN
  • No hepatitis B or C

Renal

  • Creatinine clearance at least 45 mL/min

Other

  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • HIV negative
  • Human T-cell leukemia virus type 1 (HTLV-1) negative
  • No other malignancy within the past 5 years except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix
  • No other illness that would limit study participation
  • No active serious infection not controlled by antibiotics

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • No concurrent anticancer antibody therapy
  • No concurrent anticancer immunotherapy
  • No concurrent anticancer gene therapy
  • No concurrent anticancer vaccine therapy
  • No concurrent anticancer angiogenesis inhibitors
  • No concurrent sargramostim (GM-CSF)
  • No concurrent filgrastim (G-CSF) during course 1 of therapy

Chemotherapy

  • More than 21 days since prior chemotherapy unless fully recovered
  • No concurrent anticancer chemotherapy

Endocrine therapy

  • See Disease Characteristics
  • More than 2 weeks since prior topical corticosteroids
  • No concurrent anticancer hormonal therapy

Radiotherapy

  • More than 2 weeks since prior radiotherapy
  • No concurrent radiotherapy

Surgery

  • Not specified

Other

  • More than 2 weeks since prior antineoplastic therapy
  • More than 21 days since prior investigational agents unless fully recovered
  • No concurrent citrate-blood products within 30 minutes before or after study treatment
  • No concurrent anticancer matrix metalloprotease inhibitors
  • No other concurrent anti-CTCL therapy
  • No concurrent use of tanning beds
  • No other concurrent investigational agents
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00061880


Locations
Layout table for location information
United States, Alabama
University of Alabama at Birmingham Comprehensive Cancer Center
Birmingham, Alabama, United States, 35294-3300
United States, North Carolina
Duke Comprehensive Cancer Center
Durham, North Carolina, United States, 27710
United States, Texas
University of Texas - MD Anderson Cancer Center
Houston, Texas, United States, 77030-4009
Sponsors and Collaborators
BioCryst Pharmaceuticals
Investigators
Layout table for investigator information
Study Chair: Alex Shalaurov, MD, PhD Inveresk Research Group, Incorporated
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00061880     History of Changes
Other Study ID Numbers: BIOCRYST-1777BC-103
CDR0000301763 ( Registry Identifier: PDQ (Physician Data Query) )
First Posted: June 6, 2003    Key Record Dates
Last Update Posted: May 30, 2013
Last Verified: July 2004

Keywords provided by National Cancer Institute (NCI):
recurrent cutaneous T-cell non-Hodgkin lymphoma
stage I cutaneous T-cell non-Hodgkin lymphoma
stage II cutaneous T-cell non-Hodgkin lymphoma
stage III cutaneous T-cell non-Hodgkin lymphoma
stage IV cutaneous T-cell non-Hodgkin lymphoma
 recurrent mycosis fungoides/Sezary syndrome
stage I mycosis fungoides/Sezary syndrome
stage II mycosis fungoides/Sezary syndrome
stage III mycosis fungoides/Sezary syndrome
stage IV mycosis fungoides/Sezary syndrome

Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma
Lymphoma, T-Cell
Lymphoma, T-Cell, Cutaneous
Neoplasms by Histologic Type
Neoplasms
 Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin